Drug Trial Radar · NCT01376089
Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis
Last checked: Nov 19, 2026Latest source record: Dec 19, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
304
Actual
Start
May 2011
Primary completion
Oct 2011
Study completion Feb 2012
Sponsor
- Lead sponsor
- GE HealthcareIndustry
- Sponsor type
- Industry
- Collaborators
- i3 Statprobe
- First posted
- Jun 20, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate and compare overall patient comfort profile between the Iso-osmolar contrast media (IOCM), iodixanol 320 mg I/mL, and a Low-osmolar contrast media (LOCM), iopamidol 370 mg I/mL in patients undergoing Contrast-Enhanced Computed Tomographic (CECT) imaging of the abdomen/pelvis.
Conditions
- Patient Comfort and Safety
Interventions
IodixanolDrug
Iodixanol 320 mg I/mL as a single iv. administration.
IopamidolDrug
Comparator agent iopamidol (Isovue) 370 mg I/mL as a single iv. administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of Subjects With Moderate/Severe Discomfort When Undergoing Contrast-Enhanced Computed Tomographic (CECT) Imaging of the Abdomen/Pelvis.Time frame: Within 10 minutes post contrast administration
- Frequency of Subjects With Moderate / Severe Discomfort When Undergoing Contrast-Enhanced Computed Tomographic (CECT) Imaging of the Abdomen/Pelvis.Time frame: Within 10 minutes post contrast administration.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GE Healthcare
Princeton, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.